Knowledge (XXG)

Calcimimetic

Source 📝

232: 99:(CKD) patients on hemodialysis. Etelcalcetide is administered intravenously thrice weekly at the end of each dialysis session. Etelcalcetide binds to the CaSR on the parathyroid gland, which results in receptor activation and ultimately reduction in PTH. 273: 302: 88: 266: 292: 259: 156: 40: 69: 297: 73: 36: 96: 32: 157:
William G. Goodman, "Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention"
76:(CaSR) on the parathyroid gland. As a result of the receptor "thinking" there is sufficient calcium, 77: 24: 50:
calcimimetics does not appear to affect the risk of early death. It does decrease the need for a
141: 208: 51: 243: 125:, and adynamic bone disease if intact parathyroid hormone (iPTH) levels drop below 100pg/mL. 198: 188: 239: 47: 203: 176: 286: 92: 177:"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients" 193: 122: 110: 55: 175:
Ballinger, AE; Palmer, SC; Nistor, I; Craig, JC; Strippoli, GF (9 December 2014).
39:
that is expressed in various human organ tissues. Calcimimetics are used to treat
65: 103: 80:(PTH) secretion will be reduced. Lower calcium levels will be seen as well. 68:
was the first calcimimetic to be approved. Cinacalcet mimics calcium at the
212: 118: 59: 28: 231: 114: 87:
Inc. announced that it had submitted a new drug application with the
84: 247: 95:(formerly velcalcetide), for the treatment of SHPT in 72:. This binding will increase the sensitivity of 170: 168: 267: 102:Calcimimetics can be used concomitantly with 8: 146:(on line). Last editorial review: 4/8/2004. 181:The Cochrane Database of Systematic Reviews 274: 260: 89:United States Food and Drug Administration 202: 192: 134: 46:In the treatment of SHPT patients on 7: 228: 226: 303:Systemic hormonal preparation stubs 159:Nephrology Dialysis Transplantation 246:. You can help Knowledge (XXG) by 14: 230: 113:. Common side effects include: 293:Systemic hormonal preparations 194:10.1002/14651858.CD006254.pub2 142:"Definition of calcimimetic", 1: 41:secondary hyperparathyroidism 70:parathyroid hormone receptor 54:but caused more issues with 319: 225: 109:Calcimimetic use can have 27:that mimics the action of 74:calcium-sensing receptors 91:for a new calcimimetic, 56:low blood calcium levels 37:calcium-sensing receptor 97:chronic kidney disease 33:allosteric activation 240:hormonal preparation 161:(2002) 17: 204-207. 83:On August 25, 2015 78:parathyroid hormone 25:pharmaceutical drug 16:Pharmaceutical drug 298:Receptor agonists 255: 254: 52:parathyroidectomy 310: 276: 269: 262: 234: 227: 217: 216: 206: 196: 172: 163: 154: 148: 139: 318: 317: 313: 312: 311: 309: 308: 307: 283: 282: 281: 280: 223: 221: 220: 174: 173: 166: 155: 151: 140: 136: 131: 31:on tissues, by 17: 12: 11: 5: 316: 314: 306: 305: 300: 295: 285: 284: 279: 278: 271: 264: 256: 253: 252: 235: 219: 218: 164: 149: 133: 132: 130: 127: 15: 13: 10: 9: 6: 4: 3: 2: 315: 304: 301: 299: 296: 294: 291: 290: 288: 277: 272: 270: 265: 263: 258: 257: 251: 249: 245: 242:article is a 241: 236: 233: 229: 224: 214: 210: 205: 200: 195: 190: 186: 182: 178: 171: 169: 165: 162: 160: 153: 150: 147: 145: 138: 135: 128: 126: 124: 120: 116: 112: 107: 105: 100: 98: 94: 93:etelcalcetide 90: 86: 81: 79: 75: 71: 67: 63: 61: 57: 53: 49: 44: 42: 38: 34: 30: 26: 22: 248:expanding it 237: 222: 187:: CD006254. 184: 180: 158: 152: 144:Medicine.net 143: 137: 123:hypocalcemia 111:side effects 108: 101: 82: 64: 45: 21:calcimimetic 20: 18: 287:Categories 129:References 66:Cinacalcet 106:therapy. 104:vitamin D 213:25490118 204:10614033 119:vomiting 60:vomiting 48:dialysis 43:(SHPT). 35:of the 29:calcium 211:  201:  115:nausea 238:This 85:Amgen 23:is a 244:stub 209:PMID 117:and 58:and 199:PMC 189:doi 289:: 207:. 197:. 185:12 183:. 179:. 167:^ 121:, 62:. 19:A 275:e 268:t 261:v 250:. 215:. 191::

Index

pharmaceutical drug
calcium
allosteric activation
calcium-sensing receptor
secondary hyperparathyroidism
dialysis
parathyroidectomy
low blood calcium levels
vomiting
Cinacalcet
parathyroid hormone receptor
calcium-sensing receptors
parathyroid hormone
Amgen
United States Food and Drug Administration
etelcalcetide
chronic kidney disease
vitamin D
side effects
nausea
vomiting
hypocalcemia
"Definition of calcimimetic", Medicine.net (on line). Last editorial review: 4/8/2004.
William G. Goodman, "Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention" Nephrology Dialysis Transplantation (2002) 17: 204-207.


"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients"
doi
10.1002/14651858.CD006254.pub2
PMC

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.